Study #2024-1088
A phase 3, double-blind, randomized, placebo-controlled trial of quizartinib administered in combination with induction and consolidation chemotherapy and administered as maintenance therapy in adult patients with newly diagnosed FLT3-ITD negative acute myeloid leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
Quizartinib, Chemotherapy, Placebo
Description
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Leukemia
Study phase:
Phase III
Physician name:
Naval Daver
Department:
Leukemia
For general questions about clinical trials:
1-877-581-3446
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.